Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis

Affiliations

• ¹ From the Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat) (A.P., L.M., J.C., P.M., A.V.-J., G.A., B.R.-A., J.S.-G., J.R., M.C., I.G., M.T., X.M.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Department of Internal Medicine (C.P.B.R.) and Center of Biomedical Research in Network on Neurodegenerative Diseases (CIBERNED) (C.P.B.R.), Sant Joan d'Alacant University Hospital, Alicante, Spain; Department of Neurology (A.P.), Hospital Italiano, Buenos Aires, Argentina; Department of Infectious Diseases (C.P.B.R., A.A.P., I.R.C.) and Microbiology Department (M.L.), Vall d'Hebron University Hospital, Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Toronto, Canada.
• ² From the Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat) (A.P., L.M., J.C., P.M., A.V.-J., G.A., B.R.-A., J.S.-G., J.R., M.C., I.G., M.T., X.M.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Department of Internal Medicine (C.P.B.R.) and Center of Biomedical Research in Network on Neurodegenerative Diseases (CIBERNED) (C.P.B.R.), Sant Joan d'Alacant University Hospital, Alicante, Spain; Department of Neurology (A.P.), Hospital Italiano, Buenos Aires, Argentina; Department of Infectious Diseases (C.P.B.R., A.A.P., I.R.C.) and Microbiology Department (M.L.), Vall d'Hebron University Hospital, Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Toronto, Canada. lmidaglia@cem-cat.org.